SOURCE: Hard to Treat Diseases, Inc.

March 02, 2006 10:07 ET

Hard To Treat Diseases, Incorporated Announces: Dismissal of Denver Lawsuit and Response to Appeal Brief

DELRAY BEACH, FL -- (MARKET WIRE) -- March 2, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (OTC: HTDS) announces that Shinn Capital has dismissed the Federal lawsuit against the Denver testing entities and researcher that tested Tubercin on behalf of HTTD. HTTD, as Intervenor in the case, has not dismissed its claims against Shinn Capital.

Shinn Capital filed its response to HTTD's Initial Brief filed with the U.S. Court of Appeals. The response is available on the Company's website at:

The Oklahoma court has not yet ruled on the replevin action brought by Shinn Capital. HTTD is confident that the case will be dismissed for a third time due to baseless claims.

HTTD has conducted testing on the Tubercin which the Company owns. The Company is continuing its efforts to secure rights to Tubercin through South Korea. The Company has no intention of infringing on any license agreements or marketing rights that other entities currently hold.

HTTD has also conducted testing on an additional drug which the Company owns. This drug is manufactured by a major pharmaceutical company that utilizes the drug for purposes other than those tested by HTTD. As a result of HTTD's testing, patent applications have been filed which are owned and controlled by HTTD. The Company is presently in discussions with the manufacturer in order to advance this drug for the treatments proposed in HTTD's applications. This drug and pharmaceutical company will remain confidential until negotiations are finalized.

"The Company is focusing its efforts on advancing its rights and applications for drugs that are not involved in litigation," states HTTD's CEO Colm King.

Cautionary Note Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Contact Information


    Colm J. King
    Hard to Treat Diseases, Incorporated
    (561) 278-7856